Drugs / NUV-868
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05252390 | Mar 2022 → Jul 2024 | malignant pancreatic neoplasm, ovarian carcinoma, prostate carcinoma, triple-negative breast carcinoma | Nuvation Bio Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-02-29 | Nuvation Bio Inc. | Results Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update nuvationbio.com ↗
We are pleased to announce completion of a Phase 1 monotherapy study of NUV-868 and determination of a MTD that will help inform our ongoing Phase 1b combination studies. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-02-29 | Nuvation Bio Inc. | Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update nuvationbio.com ↗ |
| 2022-12-19 | Nuvation Bio Inc. | Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868 nuvationbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUV-868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252390 ↗ |
| Route | Oral | “NUV-868 is an investigational drug for oral dosing.” NCT05252390 ↗ |